

## Scottish Testing Oversight Group – Note of meeting 1 – 1 April 2020

### Attendees:

David Crossman (chair)	SG, Chief Scientist
NR	SG, Covid-19 health policy response
NR	SG, Covid-19 health policy response
Ian Davidson	SG, Covid-19 expanded testing programme
Kate Templeton	NHS Lothian
NR	NSS, National Laboratory Programme
Jonathan Cameron	SG, Digital Health
Hugh McAloon	SG, population surveillance
Mary Black	Public Health Scotland
Jim McMenamin	Health Protection Scotland, PHS

### Note of meeting:

The purpose of the group will be to oversee the development of a Scottish testing strategy for covid-19 to ensure that we have a coordinated and effective approach to increasing testing capacity. The group has been established on the recommendation of the Chief Medical Officer to provide leadership and coordination, ensuring clarity in an increasingly complex landscape.

In order to prevent overlap of coordination mechanisms, DC will write to the CMO and First Minister to confirm the establishment and remit of this oversight group.

The group noted the six workstreams which will form the strands of the strategy:

1. Strengthening laboratory testing by increasing NHS laboratory capacity, and supporting and participating in the UK programme to deliver large-scale non-NHS testing to people in Scotland
2. Developing antibody testing
3. Supporting surveillance, epidemiology and prioritisation, including forward look to anticipate changes in testing approaches as we exit the suppression stage
4. Managing data and maximising quality of data management
5. Logistics and access to testing
6. Communications

Each member of the group gave a short readout of the priority work they are currently involved in, and how this links to the above workstreams.

Leads were identified for each of the six workstreams (see annex A).

It was agreed the group will meet Mondays, Wednesdays and Fridays at 17.00-17.30 via Zoom. Document sharing will move to Microsoft teams as soon as possible, to spare mailboxes.

## Annex A

**Strand 1 - Strengthening laboratory testing by increasing NHS laboratory capacity, and supporting and participating in the UK programme to deliver large-scale non-NHS testing to people in Scotland.**

Key contact	Area
NR	NSS
<a href="#">Ian Davidson</a>	SG/OLS
NR (tbc)	NHS

**Strand 2 - Developing antibody testing**

Key contact	Area
<a href="#">Kate Templeton</a>	Serological testing
<a href="#">David Taggart (tbc)</a>	NSS/Procurement
<a href="#">Andrew Fowlie (tbc)</a>	Industry/NHS procurement

**Strand 3 - Supporting surveillance, epidemiology and prioritisation, including forward look to anticipate changes in testing approaches as we exit the suppression stage.**

Key contact	Area
<a href="#">Mary Black</a>	PHS clinical lead
<a href="#">Jim McMenamin</a>	HPS clinical lead
<a href="#">High McAloon</a>	SG/Surveillance

**Strand 4 - Managing data and maximising quality of data management**

Key contact	Area
<a href="#">Jonathan Cameron</a>	SG/NES Digital
<a href="#">Hugh McAloon</a>	SG/Surveillance
<a href="#">Jim McMenamin / Michael Lockhart (tbc)</a>	HPS clinical lead
<a href="#">TBC</a>	DHI

**Strand 5 - Access to testing**

Key contact	Area
<a href="#">TBC, involvement from PHS</a>	

**Strand 6 – Communications**

Key contact	Area
<a href="#">TBC, SG Comms</a>	